Page 3 - Iological Marker News Today

Patients with advanced NSCLC who received optimal first-line treatment based on biomarker testing demonstrated better outcomes, new findings showed.

Recent results suggested a significant association between PTSD and a reduction in cerebellar volume, suggesting this brain area may be a new treatment target for the disorder.

"It is important to note that the more typically measured biomarkers for thyroid function (T4 and TSH) are poorly linked to free T3 levels," said researchers.

NM-101, from Terran Biosciences, is a cloud-based software platform to analyze neuromelanin-sensitive MRI scans, which could aid in the diagnosis of neurodegenerative diseases.

Transcranial direct current stimulation significantly improved cognitive function in a sham-controlled trial of patients with Alzheimer's disease.

Neuroinflammation expert Jarred Younger, PhD, disputes commentary calling for clinicians to stop prescribing the off-label compounded medication to reduce pain in people with fibromyalgia.

The FDA has rejected Clene Nanomedicine's application for accelerated approval for the experimental drug ALS drug, CNM-Au8, citing insufficient evidence.

Clinically significant ILD is believed to occur in 5%-10% of patients with RA, but robust data are lacking on how to best predict which patients face the highest risk for RA-associated ILD.

The US National Institute of Standards and Technology has developed the first human urine standard with accurate measurements of albumin.

Imaging and other tools that take advantage of developing understanding of migraine pathophysiology could eventually address difficulties in diagnosing and treating the condition.